Thanks to visit codestin.com
Credit goes to link.springer.com

Skip to main content

Advertisement

Springer Nature Link
Log in
Menu
Find a journal Publish with us Track your research
Search
Cart
  1. Home
  2. Gastric Cancer
  3. Article

Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer

  • Original article
  • Published: December 2000
  • Volume 3, pages 177–186, (2000)
  • Cite this article
Download PDF
Gastric Cancer Aims and scope Submit manuscript
Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer
Download PDF
  • Mitsugu Kochi1,
  • Masashi Fujii1,
  • Noriaki Kanamori1,
  • Teruo Kaiga1,
  • Tetsuya Kawakami1,
  • Kazuo Aizaki1,
  • Mitsuko Kasahara1,
  • Fumiro Mochizuki1,
  • Yuichi Kasakura1 &
  • …
  • Motoo Yamagata1 
  • 1655 Accesses

  • 112 Citations

  • 3 Altmetric

  • Explore all metrics

Background. This clinicopathological study evaluated the utility of serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 as predictors of locoregional recurrence and long-term disease-free survival in patients with gastric cancer.

Methods. During the period January 1989 to December 1994, 485 patients with primary gastric cancer were evaluated. Gastrectomies were performed in 434 patients. Prognostic factors were analyzed by the Kaplan-Meier method and multivariate analysis, using Cox regression.

Results. Elevated serum CEA and CA19-9 levels were observed in 92 of the 485 patients (19.0%), and in 95 of the 435 patients (21.8%), respectively, and both markers were elevated in 29 of these 435 patients (6.7%). Elevated serum CEA and CA19-9 levels correlated well with lymph node metastasis, lymphatic invasion, vessel invasion, stage grouping, depth of invasion, and curability. Patients with elevated serum CEA levels were at significantly higher risk of having all recurrence factors than were those with normal serum CEA levels. Patients with elevated serum CA19-9 levels were at significantly higher risk of having peritoneal metastases and distant metastases than were those with normal serum CA19-9 levels. A significant difference in the cumulative survival curves of patients was demonstrated between those with elevated and those with normal serum CEA or CA19-9 levels, even for patients at the same disease stage (stage III). Patients with elevated levels of both markers had a significantly worse prognosis than patients in whom the levels of both markers were normal. In patients who underwent gastrectomy, elevated serum CEA levels either preoperatively or within 3 weeks after gastrectomy were associated with significantly worse prognosis than were normal levels. When the cutoff level of serum CEA was increased to 10 ng/ml, serum CEA, age, lymph node metastasis, and surgical stage grouping were selected as independent prognostic factors by multivariate analysis of 14 prognostic factors, using Cox regression.

Conclusion. Serum CEA and CA19-9 levels provide additional prognostic information in patients with primary gastric cancer. In particular, an elevated serum CEA level provides additional prognostic information and is a useful indicator of curability in patients who undergo gastrectomy. Serum CEA level is an independent prognostic factor in patients with primary gastric cancer.

Article PDF

Download to read the full article text

Similar content being viewed by others

Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer

Article 07 March 2021

Diagnostic and prognostic value of CEA, CA19–9, AFP and CA125 for early gastric cancer

Article Open access 09 November 2017

Comparison of CEA and CA19-9 as a predictive factor for recurrence after curative gastrectomy in gastric cancer

Article Open access 03 June 2022

Explore related subjects

Discover the latest articles, books and news in related subjects, suggested using machine learning.
  • Cancers
  • Colon cancer
  • Gastric cancer
  • Gastrointestinal cancer
  • Prognosis
  • Prognostic markers
Use our pre-submission checklist

Avoid common mistakes on your manuscript.

Author information

Authors and Affiliations

  1. Third Department of Surgery, Nihon University School of Medicine, 30-1 Ohyaguchi Kamimachi, Itabashi-ku, Tokyo 173-8610, Japan, , , , , , JP

    Mitsugu Kochi, Masashi Fujii, Noriaki Kanamori, Teruo Kaiga, Tetsuya Kawakami, Kazuo Aizaki, Mitsuko Kasahara, Fumiro Mochizuki, Yuichi Kasakura & Motoo Yamagata

Authors
  1. Mitsugu Kochi
    View author publications

    Search author on:PubMed Google Scholar

  2. Masashi Fujii
    View author publications

    Search author on:PubMed Google Scholar

  3. Noriaki Kanamori
    View author publications

    Search author on:PubMed Google Scholar

  4. Teruo Kaiga
    View author publications

    Search author on:PubMed Google Scholar

  5. Tetsuya Kawakami
    View author publications

    Search author on:PubMed Google Scholar

  6. Kazuo Aizaki
    View author publications

    Search author on:PubMed Google Scholar

  7. Mitsuko Kasahara
    View author publications

    Search author on:PubMed Google Scholar

  8. Fumiro Mochizuki
    View author publications

    Search author on:PubMed Google Scholar

  9. Yuichi Kasakura
    View author publications

    Search author on:PubMed Google Scholar

  10. Motoo Yamagata
    View author publications

    Search author on:PubMed Google Scholar

Additional information

Received: June 20, 2000 / Accepted: November 14, 2000

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kochi, M., Fujii, M., Kanamori, N. et al. Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer 3, 177–186 (2000). https://doi.org/10.1007/PL00011715

Download citation

  • Issue date: December 2000

  • DOI: https://doi.org/10.1007/PL00011715

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

  • Key words Tumor marker
  • CEA
  • CA19-9
  • Gastric cancer
  • Prognosis
Use our pre-submission checklist

Avoid common mistakes on your manuscript.

Advertisement

Search

Navigation

  • Find a journal
  • Publish with us
  • Track your research

Discover content

  • Journals A-Z
  • Books A-Z

Publish with us

  • Journal finder
  • Publish your research
  • Language editing
  • Open access publishing

Products and services

  • Our products
  • Librarians
  • Societies
  • Partners and advertisers

Our brands

  • Springer
  • Nature Portfolio
  • BMC
  • Palgrave Macmillan
  • Apress
  • Discover
  • Your US state privacy rights
  • Accessibility statement
  • Terms and conditions
  • Privacy policy
  • Help and support
  • Legal notice
  • Cancel contracts here

132.145.61.108

Not affiliated

Springer Nature

© 2025 Springer Nature